Johnson & Johnson

“Johnson & Johnson is one of the highest-quality healthcare businesses in the world — AAA-rated, $19B+ annual FCF, a wide multi-layered moat, and a 62-year dividend growth record — but current valuation at ~18x forward earnings offers an adequate, not exceptional, return profile of ~9% annually. The Stelara biosimilar erosion creates a real 2-3 year earnings headwind that the oncology pipeline is positioned but not guaranteed to absorb, and management alignment is process-driven rather than ownership-driven, with the Texas Two-Step talc maneuver as a reputational blemish. At sub-$200 (below ~16x forward), risk/reward becomes materially more compelling; at current prices, capital can wait for a better entry without sacrificing thesis integrity.”